Product logins

Find logins to all Clarivate products below.


Osteoarthritic Pain | Treatment Algorithms | Claims Data Analysis | US | 2025

Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and AEDs, are prescribed to alleviate the pain and enhance mobility, but more-effective, well-tolerated alternatives are needed. In this crowded and largely generic market, a deep understanding of treatment patterns is essential for the successful introduction of a novel analgesic.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OA pain patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OA pain patients?
  • How has Zilretta been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of OA pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of OA pain patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Pacira Biosciences, Collegium Pharmaceuticals, Protega Pharmaceuticals, Averitas Pharma, Kowa

Key drugs: Zilretta, NSAIDs, gabapentin, intra-articular corticosteroids, celecoxib, Xtampza ER, Qutenza, Nucynta, tramadol

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelofibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Myelofibrosis is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The only…
Report
Bispecific Therapies – Access & Reimbursement – Access & Reimbursement – Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma (US)
Bispecific therapies provide a valuable treatment option in hematological cancers, offering an “off-the-shelf” option for oncologists to treat patients with B-cell Non-Hodgkin’s lymphoma or…
Report
Alopecia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The immune system mistakenly targets anagen hair follicles. While topical…
Report
Chronic Kidney Disease – Unmet Need – Unmet Need – Chronic Kidney Disease (US/EU)
Chronic kidney disease (CKD) encompasses a set of heterogeneous disorders that gradually damage the kidney’s structure or function. The CKD treatment landscape continues to evolve as the adoption…